Literature DB >> 2578415

A complete regulatory loop between the immune and neuroendocrine systems.

J E Blalock, E M Smith.   

Abstract

Infection of lymphocytes with Newcastle disease virus induces the cells to synthesize immunoreactive (ir) adrenocorticotropin (ACTH) and endorphins. The irACTH is synthesized de novo, and common properties of lymphocyte and pituitary ACTH include: antigenicity, bioactivity, molecular weight, and retention time on reverse phase high-pressure liquid chromatography. The irACTH appears to be active in vivo because a rise in serum corticosterone levels in hypophysectomized mice corresponds with spleen cell production of irACTH. Furthermore, preliminary experiments showed that B cell depletion blocked the normal rise in serum corticosterone levels after herpes simplex virus infection of intact mice. It seems that a similar system operates in vivo in humans. Typhoid vaccine, which induces lymphocyte-derived irACTH production in vitro, caused a time-dependent increase in the number of irACTH-positive lymphocytes in both hypopituitarism and normal short children. A rise in serum cortisol levels was seen in one patient with hypopituitarism and all normal patients. The above regulatory circuit also seems able to act in the reverse direction. Pituitary ACTH and alpha-endorphin can behave like lymphokines by being immunosuppressive at 0.5 microM in an in vitro antibody synthesis system. Further, lymphocytes were shown to have high-affinity receptors for both of these hormones. Thus, it appears that the immune and neuroendocrine systems have the ability to signal each other through common or related peptide hormones and receptors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2578415

Source DB:  PubMed          Journal:  Fed Proc        ISSN: 0014-9446


  20 in total

Review 1.  Hormones and the immune response.

Authors:  A K Bhalla
Journal:  Ann Rheum Dis       Date:  1989-01       Impact factor: 19.103

2.  The rat female protein, a pentraxin with lectinic properties.

Authors:  R Schade; W Bürger; A M Ladhoff; C Pfister; E Nugel
Journal:  Agents Actions       Date:  1991-11

3.  Evidence of a plasma-mediated "window" of immunodeficiency in rats following trauma.

Authors:  C D Mills; M D Caldwell; D S Gann
Journal:  J Clin Immunol       Date:  1989-03       Impact factor: 8.317

4.  A central nervous system defect in biosynthesis of corticotropin-releasing hormone is associated with susceptibility to streptococcal cell wall-induced arthritis in Lewis rats.

Authors:  E M Sternberg; W S Young; R Bernardini; A E Calogero; G P Chrousos; P W Gold; R L Wilder
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

5.  Methionine-enkephalin as immunomodulator therapy in human immunodeficiency virus infections: clinical and immunological effects.

Authors:  K M Zunich; C H Kirkpatrick
Journal:  J Clin Immunol       Date:  1988-03       Impact factor: 8.317

Review 6.  Immunomodulating peptides.

Authors:  G H Werner; F Floc'h; D Migliore-Samour; P Jollès
Journal:  Experientia       Date:  1986-05-15

Review 7.  Neural and Pavlovian influences on immunity.

Authors:  R W Brittain; N I Wiener
Journal:  Pavlov J Biol Sci       Date:  1985 Oct-Dec

8.  Nucleotide and amino acid sequence of lymphocyte-derived corticotropin: endotoxin induction of a truncated peptide.

Authors:  E M Smith; F S Galin; R D LeBoeuf; D H Coppenhaver; D V Harbour; J E Blalock
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

9.  Administration of structured lipid composed of MCT and fish oil reduces net protein catabolism in enterally fed burned rats.

Authors:  T C Teo; S J DeMichele; K M Selleck; V K Babayan; G L Blackburn; B R Bistrian
Journal:  Ann Surg       Date:  1989-07       Impact factor: 12.969

10.  Immune system control of rat and rabbit colonic electrolyte transport. Role of prostaglandins and enteric nervous system.

Authors:  M J Bern; C W Sturbaum; S S Karayalcin; H M Berschneider; J T Wachsman; D W Powell
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.